Minerva Neurosciences Announces Positive Top Line Results From Phase Ib Clinical Trial in Major Depressive Disorder With MIN-202
March 11, 2016 08:30 ET
|
Minerva Neurosciences, Inc
Treatment with selective orexin-2 receptor antagonist observed to be well tolerated and to improve symptoms of depression, independent from its effect on sleep WALTHAM, Mass., March 11, 2016 ...
Fact Sheet: Managing Treatment For Individuals With Major Depressive Disorder (MDD) - Top 10 New Resources On PsychU
March 16, 2015 14:36 ET
|
PsychU
GETTYSBURG, Pa., March 16, 2015 (GLOBE NEWSWIRE) -- Fact Sheet | New articles, resources, and presentations related to managing treatment for individuals with major depressive disorder (MDD) now...
Neuronetics, Inc. Raises $30 Million in Series E Financing
May 16, 2011 08:30 ET
|
Neuronetics
MALVERN, PA--(Marketwire - May 16, 2011) - Neuronetics, Inc., maker of the NeuroStar TMS (Transcranial Magnetic Stimulation) Therapy® System for the treatment of major depression*, announced today...
New Trial Data Confirm Clinical Effectiveness and Good Adherence Rates With NeuroStar TMS Therapy in Patients With Major Depressive Disorder Treated in a Real World Practice Setting
May 15, 2011 19:00 ET
|
Neuronetics
HONOLULU, HI--(Marketwire - May 15, 2011) - Results of a Neuronetics-sponsored, multisite observational study of patients with major depressive disorder (MDD) treated with Neuronetics' NeuroStar...
Neuronetics Receives TiE50 Award for Technology Entrepreneurship
May 09, 2011 08:30 ET
|
Neuronetics
MALVERN, PA--(Marketwire - May 9, 2011) - Neuronetics, Inc., maker of the NeuroStar Transcranial Magnetic Stimulation (TMS) Therapy® System, has been selected by TiE Silicon Valley as a 2011 recipient...
New Data Show No Negative Long-Term Effect in Cognitive Function in Patients With Major Depressive Disorder Treated With NeuroStar TMS Therapy(R)
April 14, 2011 13:30 ET
|
Neuronetics
HONOLULU, HI--(Marketwire - Apr 14, 2011) - In an open-label study of patients with major depressive disorder (MDD) who had not benefitted from prior antidepressant medication and were treated with...
Neuronetics Appoints Vice President of Health Policy and Government Relations
March 02, 2011 08:00 ET
|
Neuronetics
MALVERN, PA--(Marketwire - March 2, 2011) - Neuronetics, Inc. today announced that Mary Hailey, an industry executive with more than 25 years of experience in designing and implementing healthcare...
NeuroStar TMS Therapy Continues to Grow as a Standard of Care for Patients With Depression
January 10, 2011 13:13 ET
|
Neuronetics
MALVERN, PA--(Marketwire - January 10, 2011) - Neuronetics, Inc., is pleased to announce that effective January 1, 2011, new Category I CPT® codes are available for billing the medical...